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Abstract   
 
Background:  Many people suffer from alcoholism which can be a debilitating disease. With only 
three medications on the market to treat alcoholism, research to find new pharmaceuticals is important.  
The recent publication of a book promoting baclofen, a GABA agonist normally used to treat 
spasticity, as a treatment for alcoholism, has brought public attention to the topic. For potential patients 
who have read the book and clinicians who treat alcoholism, this systematic review examines claims 
that baclofen decreases alcohol cravings and has a possible clinical use in the treatment of alcoholism.  
 
Methods:  An exhaustive search of available medical literature, published in English, was conducted 
using MEDLINE, Evidence-Based Medicine Reviews Multifile, and CINAHL with the keywords 
“baclofen” and “alcoholism.” A bibliographical search of the literature was done to find further articles 
and information. Each study needed to evaluate both abstinence and craving for alcohol. Due to the 
fact that there is limited research available on the topic, all available articles were included. 
 
Results:  The search yielded 2 random controlled trials, 2 open label studies, and 3 case reports. Both 
random controlled trials (RCT) showed statistically significant results in increased abstinence and 
decreased craving in baclofen versus placebo group. Both open label studies showed decreased craving 
with baclofen use, and one showed increased abstinence, while the other showed a decrease in alcohol 
consumption. All three case reports described accounts of severe alcoholics whose alcoholism was 
successfully treated with higher doses of baclofen.  Minimal to no side effects were seen in all trials 
and no patients described craving or euphoric effects from taking baclofen. 
 
Conclusion:  Even with the need for more research on the topic, baclofen should be considered as 
another medication to try in the treatment of alcoholism. Patients with intense cravings for alcohol may 
have greater benefit in cessation of alcohol use as baclofen significantly and quickly decreases 
cravings. Both the high safety and low side effect profile make baclofen a reasonable option to try. 
Since the amount of research on the topic is minimal, clinicians need to use their judgment and may 
want to try baclofen only after first attempting other treatment options. The duration and dosage of 
baclofen is uncertain and will need to be adjusted on a patient by patient basis.  
 
 
Keywords:  baclofen, alcoholism 
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The Efficacy of Baclofen in Reducing Alcohol Consumption and Decreasing Alcohol Craving in 
Alcohol Dependent Adults 
 
 
BACKGROUND 
 Worldwide, alcohol causes 1.8 million deaths (3.2% of total) and is the fifth leading cause of 
premature death and disability in the world according to the WHO.1,2  People who suffer from 
alcoholism are at increased risk for liver cirrhosis, pancreatic diseases, and accidents.2 With such 
detrimental effects and such a large number of individuals suffering from alcoholism, there is a great 
deal of discussion around the topic. The recent American release (2008) of a book called, The End of 
My Addiction, by Olivier Ameisen,3 a French cardiologist, has brought increased attention on a drug 
called baclofen as a “cure” for alcoholism. In his book, Ameisen claims to have successfully 
suppressed his alcoholic cravings by taking high dose baclofen and thus “curing” his alcoholism. This 
medication is typically used to treat spasticity, and he believes its physiological actions could indicate 
it in the treatment of alcoholism.3 
Alcoholism is a multifaceted disease originating from genetic disposition and environmental 
factors 4 and can manifest itself in various subtypes of alcohol dependent patients.5 Most 
pharmacological treatments for alcoholism focus on the craving for alcohol which is thought, in part, 
to involve gamma aminobutyric acid (GABA) dysregulation. Baclofen is a GABA B-receptor agonist, 
and may help this dysregulation in certain alcoholics.5  Alcohol craving can be from the desire to gain 
the positive effects from drinking alcohol which are transmitted through multiple neurochemical 
systems.6 Based on the Three Dimensional Psychobiological Model by Verheul,7 one type of craving, 
relief craving, is described as a desire to decrease tension or minimize negative emotional states. Relief 
craving is thought to be caused by a “GABAergic/glutamatergic dysregulation.”5 GABA is an 
inhibitory neurotransmitter that can promote a sense of calm. A decrease in GABA, either from 
genetics or from a personality trait is thought to be a factor in some individuals with high anxiety.5  
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Alcohol, via the corticomesolimbic pathway causes the release of GABA along with other 
neurotransmitters such as: opioids, serotonin, glutamate, and acetylcholine.6 After chronic use of 
alcohol the balance of this pathway is affected and adaptations are made by the system to maintain 
balance when alcohol is withdrawn. This leads to alcohol withdrawal symptoms and a craving to drink 
in order to avoid the discomfort of withdrawal.6  
Although baclofen’s exact mechanism of action is unknown, as a GABA agonist, it is believed 
to play a part in the regulation of GABA.8 In its current treatment for spasticity, it is approved by the 
Food and Drug Administration (FDA) in titrated amounts up to 80 mg/day, given on a three times daily 
schedule.8 In patients with multiple sclerosis, baclofen has been found to be safe in doses up to 270 
mg/day.9 The common side effects of baclofen (>10%) are muscle weakness and central nervous 
system (CNS) depression to include drowsiness, vertigo, dizziness, and insomnia.10 
The treatment for alcoholism is a multidisciplinary treatment combining pharmacological 
agents and psychosocial therapy to alter an alcoholic’s lifestyle and to encourage abstinence from all 
alcohol use. Currently, there are three agents approved by the FDA for the treatment of alcohol 
dependence. Disulfiram changes alcohol metabolism thereby causing unpleasant effects after alcohol 
consumption.6 Naltrexone works by interacting with the opioid and dopamine systems and may help 
decrease craving.6 Acamprosate helps maintain abstinence, and its exact mechanism is not yet 
understood.6 Although each of these drugs has shown some efficacy,11-13 each drug has its limitations 
and there are studies that show modest to no efficacy in long term treatment of alcohol dependence.13-
15 Thus, there is a need to pursue additional pharmaceutical agents with which to treat alcoholism. This 
systematic review examined original research that looks at the efficacy of baclofen for alcohol 
dependence and to reduce alcohol craving. 
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METHODS 
An exhaustive literature search was performed in MEDLINE, CINAHL, and Evidence-Based 
Medicine Reviews Multifile, using the search terms “alcoholism” and “baclofen.” A bibliographical 
search of the literature was done to find further articles and information. Web of Science was used to 
search forward to see if the found literature, was cited in any recent relevant studies. To find current 
trials being conducted, clinicaltrials.gov was searched using the key words baclofen and alcoholism.  
Inclusion criteria were all trials, including case reports, that were published in English. All 
participants had to be diagnosed with alcohol dependence based on DSM-IV criteria. Each study 
needed to evaluate both abstinence and craving for alcohol. Due to the fact that there is limited 
research available on the topic, all available articles were included. 
All trials were evaluated using an originally designed scoring system to assess validity (see 
table II and table III).  Scoring was based on the type of trial, the randomization of the trial, the 
description of randomization, the blinding within the trial, the blinding method, and the description of 
drop-outs. The scoring system also took into account that the craving results were based on a specified 
validated scaling system, and alcoholic drinks as recorded by participants and family members. The 
validity scale was used to assess the studies but was not used as exclusion criterion.  
 
RESULTS 
After the exhaustive search, 2 randomized controlled trials (RCT), 2 open label studies, and 3 
case reports were found from the electronic search. All 7 studies were included in the review.  
Each trial was evaluated on abstinence from alcohol, craving for alcohol, and side effects. 
Doses of baclofen are given on a three times daily schedule in all trials. All the randomized controlled 
trials and open label studies have, as part of their experimental design, some type of psychological 
counseling. Counseling type and amount of counseling differed between studies. Each of the 
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participants in the case studies had previously failed to complete numerous treatments, be it 
psychological counseling and/or pharmacotherapies. Characteristics of each study can be found in the 
characteristics of reviewed articles table (see table I). A summary of results for each article can be 
found in the summary table (see table IV). 
 
Randomized Controlled Trials 
In 2002, Addolorato et al16 published the first RCT on the efficacy of baclofen.  The study 
received a validity score of 7/8 and missed one point because there was no description of 
randomization. Thirty-nine alcohol dependent adults were randomized (randomization type not 
specified); 20 in the baclofen group and 19 in the placebo group. The baclofen group was given 15 
mg/day of baclofen for 3 days and then 30 mg/day of baclofen for the remainder of the 4 weeks.  
Participants had referred family members to aid in the administration of the drug, baclofen or placebo. 
In the baclofen group, 14/20 remained abstinent, 4/19 remained abstinent in the placebo group. Drop-
outs were considered to have relapsed. The p value was calculated to <0.005 and the number needed to 
treat (NNT) was 2. These are statistically significant results, but imprecise due to small sample size. 
The Obsessive Compulsive Drinking Scale (OCDS) was used to measure craving and showed a mean 
value at baseline for the baclofen group of 26 and placebo group of 22. The score after 4 weeks was 
about 6 for the baclofen group and 12 for the placebo group with a p value < 0.05. No patient dropped 
out of study due to side effects. Baclofen/placebo side effects were: sleepiness 2/0, tiredness 1/0 
vertigo 1/0, abdominal pain 0/1. All side effects resolved within 1-2 weeks. 
In 2007, Addolorato et al17 looked at efficacy and safety of baclofen for treatment of 
alcoholism in alcoholic adults with liver cirrhosis. With an improved experimental design, this trial 
received a validity score of 8/8. Eighty-four participants were randomized (balanced with blocks), 42 
into baclofen group, 42 into placebo group. Each group was assessed for similarities such as age, sex, 
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employment, marital status, and education. The baclofen group was given 15 mg/day of baclofen for 3 
days and then 30 mg/day of baclofen for the remainder of the 12 weeks. Participants had referred 
family members to aid in the administration of the drug, baclofen or placebo. In the baclofen group, 
30/42 remained abstinent and 12/42 remained abstinent in the placebo group. Drop-outs were 
considered to be relapsed. An odds ratio of 6.3 [95% CI 2.4-16.1] with a p value of 0.0001 and a NNT 
of 2.3 was calculated for abstinence results. The OCDS score showed a mean value at baseline for the 
baclofen group at about 27 and for the placebo group at about 25. The scores after 12 weeks was about 
3 for the baclofen group and 7 for the placebo group, with a p value of 0.0004. All results were 
considered statistically significant. No participants dropped out due to side effects. The side effects 
recorded for baclofen/placebo: headache 4/4, tiredness 1/1, vertigo 2/1, sleepiness 1/0. Hepatic safety 
was evaluated by testing liver enzymes. Participants in the baclofen group had statistically significant 
decreases in alanine aminotransferase (p=0.0195), gamma glutamyltransferase (p=0.0155), bilirubin 
(p=0.0318), and international normalized ratio (p=0.0140) in comparison to the placebo group. 
Albumin levels were elevated in the group allocated baclofen with a p value<0.0001, which is also 
statistically significant. There were no significant changes in mean cellular volume, aspartate 
aminotransferase, or creatinine.    
 
Open Label Studies 
A preliminary open label study was done in 2000 by Addolorato et al.18 Its validity score was 
3/10 for using a validated scaling system to measure craving, having family members distribute the 
medication, and accounting for all drop-outs. Ten alcohol dependent male adults enrolled in the study. 
One participant dropped out of the study and was excluded from statistical analysis. Each participant 
was given 15 mg/day of baclofen for 3 days and then 30 mg/day of baclofen for the remainder of the 4 
weeks. Participants had referred family members to aid in the administration of the baclofen. 7/9 
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patients remained abstinent throughout experimental period of 4 weeks. The Alcohol Craving Scale 
(ACS) was used to measure craving. At baseline patients had median score of 9 with actual results 
ranging from 3-14 and at end of week 4, a median score of 0 with actual results of 0-4. No additional 
participants dropped out of the study due to side effects. All side effects (headache, vertigo, sleepiness, 
tiredness, abdominal pain, and constipation) resolved after 1-2 weeks of first taking baclofen. 
At the University of North Carolina in Chapel Hill, in 2004, Flannery et al19 conducted a 
preliminary open label study. Its validity score was 2/8 because it did account for all drop outs and 
used a validated scaling system for craving. Twelve alcohol dependent adults (9 men, 3 women) 
qualified for the study.  Of the twelve, 4 were diagnosed with depression and 2 of these were being 
treated with medication for depression. Each participant was given 15 mg/day of baclofen for 3 days 
and then 30 mg/day of baclofen for the remainder of the 12 weeks. The Penn Alcohol Craving Scale 
(PACS) was used to measure craving. Participants administered their own medication. No patient 
remained abstinent throughout the 12 week study. Only 4/12 participants finished all 12 weeks of the 
study. Number of drinks/day at baseline were 7.6 ±2.2 and during treatment on average 4.7 ± 3.5 a 
decrease of 61.8% (p<0.01). Patients were abstinent 9.4±10.6% of the time at baseline and 31.0±34.2% 
of treatment days (p<0.01). Two participants in the study increased their rates of heavy drinking and 3 
participants had fewer abstinence days during treatment. Craving scores reduced significantly at 
p<0.01. Baseline PACS scores 18.4±5.1 decreased to 12.4±5.4 by end of treatment. All statistics were 
calculated based on the number of days each patient was treated prior to dropping out. Two patients 
dropped out due to side effects.   
 
Case Studies 
Dr. Olivier Ameisen, the author of the book, The End of my Addiction,3 wrote a case report 
based on his experiences taking baclofen and this was published in 2005.20 The validity score for this 
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article is 0/8. He was a 50 year old male, diagnosed with alcohol dependence and comorbid anxiety. 
He began taking baclofen at 30 mg/day and remained abstinent from that time forward (9 months at 
time of publication of the study). He increased his baclofen dosing 20 mg every third day until a max 
of 270 mg/day. At 120 mg/day his anxiety was controlled, and he had a complete absence of craving at 
270 mg/day. He experienced somnolence at 270 mg/day and decreased his dose to a maintenance dose 
of 120 mg/day with 40 mg as needed for stressful occasions. At 120 mg/day, Ameisen experienced no 
side effects.  No scales were used, all results were based on personal perspective.   
One year later, in 2007, a case report by William Bucknam,21 an addiction psychiatrist, was 
published. This article has a validity score of 0/8. A 59 year old, alcohol dependent male with anxiety 
and major depressive disorder was treated with baclofen. Scales were not used to assess craving, all 
results were based on the patient’s personal perspective. Over a month, the patient took increased 
doses of baclofen up to 100 mg/day. According to Bucknam, the patient reported a “complete 
satisfactory response. Drinking was now an alien world to him.”  During stressful occasions, 
participant took 140 mg/day. The patient occasionally chose to drink, but never had more than 3 drinks 
on one occasion or 12 per week. In addition to baclofen, the patient was taking paroxetine for his 
anxiety. He experienced no side effects from baclofen. 
In 2007, a report by Agabio et al22 was published about a schizophrenic, 55 year old, alcohol 
dependent male who was treated with 30 mg/day of baclofen for his alcoholism. He remained abstinent 
for 18 weeks at which point, he consumed one drink. His baclofen dose was increased to 75 mg/day. 
After one year on baclofen, the patient had only consumed the one drink. His craving was assessed 
using the OCDS scale and his scores went from 34 at baseline to an average of less than 10. He 
experienced mild sedation at the beginning of treatment as his only side effect and this resolved. 
Because OCDS was used as a scaling system for craving, the validity score for this report was 1/8. 
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DISCUSSION 
Limitation of Study 
As a result of the lack of research on the topic of baclofen as treatment for alcoholism, all 
located articles were included in this study. The variety of study types makes it difficult to make solid 
conclusions. The participants in each study varied significantly, but in all, encompassed the common 
population seen to have alcoholism. The most evident and important limitation to all of these studies is 
the lack of participants.  
Both RCTs had experimental design flaws. Addolorato et al16 2002 never describes the type of 
randomization used and does not discuss if the groups are equal in terms of support systems, family, 
job stability, age, or sex. Addolorato et al17 2007 improved on these design flaws. Both articles need a 
standardized method of recording alcohol intake versus relying on patients and their families to record 
intake. Also, Addolorato et al16 2002 was only 4 weeks in duration as compared to Addolorato et al17 
2007 was only 12 weeks.   
The open label studies are limited in validity due to their design. Both studies were also of short 
duration. In Flannery et al19 2004, no participants remained abstinent which made it unique from all the 
other reports. The study had low intensity psychosocial counseling; it recruited participants who were 
interested in reducing their alcohol intake, not in abstaining from alcohol, nor did it have family 
members aiding in the dispensing of baclofen. These design flaws could be responsible for the 
questionable results.   
The case studies are the least valid as they are single case reports. Ameisen20 2005 has 
increased bias because it was a self report and no one else was involved in his treatment or monitoring 
his results. Each participant varied significantly with their comorbid diagnosis: Ameisen was 
depressed20, Bucknam’s 21 patient had anxiety and major depressive disorder, and Agabio’s22 patient 
had schizophrenia. Bucknam’s21 patient was taking paroxetine in addition to the baclofen, suggesting 
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that the combination of both medications could have contributed to his results. These studies also used 
significantly higher doses of baclofen for treatment than those in the RCTs16, 17 and the open label 
studies18, 19.  The advantage of these studies was the duration of time each patient was followed, which 
amounted to about a year for each patient. 
 
Baclofen and Craving 
All trials demonstrated a decrease in alcohol craving with the use of baclofen. In all the trials, 
the largest decrease in craving occurred the first week of treatment. It could be assumed that the quick 
relief of craving, attributable to baclofen, aided in the increased ability for a patient to remain 
abstinent. In both RCTs,16, 17 there was also a drop in craving scores in the placebo group, although not 
as significant as in the baclofen group. This could be attributed to psychological counseling, personal 
focus on abstaining, and to medical management. In the case of Ameisen,20 he felt complete 
suppression of craving and “indifferent” to alcohol at 270 mg/day, suggesting that it may require high 
doses of baclofen to increase the ability for patients to decrease cravings. At 100 mg/day, Bucknam’s21 
patient had enough control over his cravings, that if he chose to drink, he was able to drink three drinks 
per occasion and stop drinking. Based on these clinical trials, baclofen decreases the craving for 
alcohol. 
 
Baclofen and Abstinence 
Abstinence from alcohol is the only true treatment for alcoholism. Until complete absence from 
alcohol consumption is achieved, damage to the body still occurs. In Addolorato et al17 2007, the 
abstinence rates in baclofen versus placebo had p values <0.0001 and an odds ratio of 6.3 with a 
confidence interval of 2.4-16.1 concluding that the results were statistically significant. There is some 
lack of precision due to the small sample size. The number needed to treat was calculated at 2.3 which 
16 
 
is a remarkable result. Addolorato etal16 2002, has similar results with a p value <0.005, and a number 
needed to treat at 2 (confidence interval was not calculated). These RCTs conclude that the efficacy of 
baclofen in treating alcoholism is substantial. 
The open label studies, as one would expect, were not as conclusive as the RCTs. Flannery et 
al19 2004 had no participants who remained abstinent throughout the entire trial period. A decrease in 
alcohol usage and an increase in abstinent days was shown to be statistically significant when 
participants were taking baclofen. Interestingly, 2 participants in the study increased their rates of 
heavy drinking and 3 participants had fewer abstinence days during treatment. The results from this 
article are difficult to assess considering only one-third of the patients finished the trial, and all 
statistics were calculated based on the number of days treated before the patients dropped out. This and 
a poor study design decreases validity in the results. Addolorato et al16 2002, an open label study, 
showed that 7/9 participants remained abstinent.   
All of the case reports showed life altering benefits to baclofen use.20-22 All three patients were 
abstinent and remained abstinent for about 1 year until each study was published and all were still 
taking baclofen. The most significant aspect of the studies was the increased dosage of baclofen. 
Although these are not valid reports, it does raise the question of whether higher doses of baclofen are 
needed in some patients to get the desired results, or if conversely, if higher doses of baclofen yield 
better results. 
  
 
Baclofen Side Effects and Safety 
The most common side effect seen in all the studies was CNS depression. Most of these side 
effects resolved within 1-2 weeks of continuous use of baclofen. In only one study, did participants 
drop out due to side effects.19 The small side effect profile makes baclofen a medication that patients 
are likely to be compliant with.  
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The safety of baclofen has been shown in each of these studies, as no participant suffered any 
single organ or systemic event that would lead to the need to discontinue the drug. In accordance, it 
was found that patients with liver cirrhosis who took baclofen showed no hepatic side effects. Liver 
enzymes improved with the use of baclofen and the absence of alcohol intake.17 Baclofen has minimal 
metabolization in the liver.10 Creatinine clearance did not differ between the baclofen and placebo 
groups showing baclofen does not cause renal damage.17 A high dose of baclofen for long term use in 
the treatment of multiple sclerosis has been shown to be safe.9 It can be assumed that using high doses 
for the treatment of alcoholism would also be safe. Another important consideration for the safety of 
baclofen is the abuse potential. No participant in any of the studies had cravings for baclofen and no 
one had any euphoric events when taking baclofen, suggesting abuse potential is very low.   
 
Baclofen and Alcoholism Treatment 
The treatment of alcohol dependence is as complicated as the disease itself and requires 
psychological counseling combined with pharmaceutical agents. It is important to consider, in each of 
these trials, the role of psychological counseling in recovery. Since each study used different 
counseling methods, it is difficult to compare the effects of counseling. Another key factor is the desire 
each patient had to stop drinking. Each patient must have had enough motivation to take the 
medication and attend the counseling sessions. Baclofen is typically given on a three times daily 
schedule which requires more dedication from the patient. As a result, in general, compliance of 
patients taking baclofen may be low. Another key issue to alcohol treatment is maintaining abstinence. 
None of these studies looked at relapse rate after stopping baclofen. Throughout the systematic review, 
no articles were found that addressed how long a patient must stay on baclofen to treat alcoholism. The 
efficacy of baclofen may be altered if a patient develops dependency symptoms with the cessation of 
baclofen. Another consideration is the long term use of baclofen and if it continues to be effective over 
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time. Since baclofen is a generic drug, the cost is substantially lower than the other medications used to 
treat alcoholism. This is a very important factor, as many patients suffering from alcoholism have 
limited financial resources.10 Baclofen as an agent to combat alcoholism appears promising. More 
research needs to be conducted with larger RCTs and longer duration of treatment with follow up after 
cessation of baclofen use. It would also be useful to see if a combination of baclofen with other alcohol 
treatment drugs increased treatment efficacy. 
 
CONCLUSION 
Baclofen should be considered as another medication to try in the treatment of alcoholism. 
Patients with intense cravings for alcohol may have greater benefit in cessation of alcohol use as 
baclofen significantly and quickly decreases cravings. Both the high safety and low side effect profile 
make baclofen a reasonable option to try. Since the amount of research on the topic is minimal, 
clinicians need to use their judgment and may want to try baclofen only after first attempting other 
treatment options. The duration and dosage of baclofen is uncertain and will need to be adjusted on a 
patient by patient basis.  
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TABLES 
 
Table I: Characteristics of Reviewed Articles 
 
Author and 
Journal 
Addolorato 
et al16 
Alcohol and 
Alcoholism 
Addolorato 
et al17 
The Lancet 
Addolorato 
et al18 
Alcoholism: 
Clinical and 
Experimental 
Research 
Flannery et 
al19 
Alcoholism: 
Clinical and 
Experimental 
Research 
Ameisen, 
O.20 
Alcohol and 
Alcoholism 
Bucknam 
W.21 
Alcohol 
and 
Alcoholism 
Agabio et al22 
Journal of 
psycho-
pharmacology 
Date 
published 2002 2007 2000 2004 2005 2007 2007 
Type of 
study 
Randomized 
controlled 
study 
Randomized 
controlled 
study 
Open label 
study 
Open label 
study 
Self Case 
Report 
Case 
Report Case Report 
Participants/ 
population 
20 baclofen 
group 
19 placebo 
group 
42 baclofen 
group 
42  placebo 
group 
 
Note: all 
participants 
have liver 
cirrhosis 
10 males 
 
 
 
 
 
 
Note: 34-54 y/o 
9 men, 3 
women 
 
 
 
 
Note: 4/12 
diagnosed with 
depression 
50 y/o male 
 
 
 
 
 
Note: 
Diagnosis of 
anxiety 
disorder* 
59 y/o 
male 
 
 
Note: 
diagnosis of 
major 
depressive 
disorder and 
anxiety 
55 y/o male 
 
 
 
 
 
 
Note: diagnosis of 
schizophrenia 
Intervention 
Baclofen 15 
mg/day for 
3 days, then 
30 mg/day 
for 27 days 
Baclofen 15 
mg/day for 
3 days, then 
30 mg/day 
for 87 days 
Baclofen 15 
mg/day for 3 
days, then 30 
mg/day for 
27 days 
Baclofen 15 
mg/day for 3 
days, then 30 
mg/day for 
27 days 
Baclofen 30 
mg/day, 
adding 20 
mg/day 
every 3 days 
until max of 
270 mg/day 
Additional 
20-40 mg 
dose as 
needed 
Maintenance 
dose 120 
mg/day 
Increased 
dose to 
max of 
100mg/day 
-Used  
additional 
40 mg/day 
as needed 
for stress 
Baclofen 30 
mg/day for 18 
weeks 
-Increased 
dose to 75 
mg/day for 
rest of the 
year 
Validity 
score (0-8) 7/8 8/8 3/8 2/8 0/8 0/8 1/8 
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Table II: Validity Scoring System 
 
Criterion Score +1 Score 0 
Trial type Randomized controlled trials  Open label study, Case studies 
Randomization Study was described as randomized Study was not described as randomized 
Randomization description Method to randomize was described 
and appropriate 
Method of randomization was not 
described 
Blinded Study was double blinded Study was not double blinded 
Blinding method Method of blinding was described Method of blinding was not described 
Drop-outs Drop-outs were described Drop-outs were not described 
Craving Results based on validated 
scaling system 
Validated scaling system used No validated scaling system used 
Referred family member to aid in 
distribution of medication and help 
record number of drinks 
Referred family member used Referred family member not used 
 
 
 
 
 
 
Table III: Validity Scores for Reviewed Articles 
 
Criterion (Scores 1 
point for each) 
Addolorato 
et al 200216 
Addolorato 
et al 200717 
Addolorato 
et al 200018 
Flannery 
et al 
200419 
Ameisen 
200520 
Bucknam 
200721 
Agabio et 
al 200722 
Trial type 1 1 0 0 0 0 0 
Randomization 0 1 0 0 0 0 0 
Randomization 
description 1 1 0 0 0 0 0 
Blinded 1 1 0 0 0 0 0 
Blinding method 1 1 0 0 0 0 0 
Drop-outs 1 1 1 1 0 0 0 
Craving Results 
based on validated 
scaling system 
1 1 1 1 0 0 1 
Referred family 
member to aid in 
distribution of 
medication and help 
record number of 
drinks 
1 1 1 0 0 0 0 
Total Score 7 8 3 2 0 0 1 
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Table IV: Summary of Results 
 
Study Addolorato 
et al 200216 
Addolorato 
et al 200717 
Addolorato 
et al 200018 
Flannery et 
al 200419 
Ameisen 
200520 
Bucknam 
200721 
Agabio et al 
200722 
Abstinence Baclofen: 
14/20 
Placebo: 
4/19 
Baclofen: 
30/42 
Placebo: 
12/42 
Baclofen: 
7/9 
Baclofen: 
0/12 
Baclofen: 
1/1 
Baclofen: 
1/1 
Baclofen: 
1/1 
p value 
NNT* 
95 % CI** 
<0.005 
2 
N/A 
<0.0001 
2.3 
2.4-16.1 
N/A N/A N/A N/A N/A 
Craving scale OCDS OCDS ACS PACS None used None used OCDS 
Mean craving 
baseline 
value 
Baclofen≈26 
Placebo≈22 
Baclofen≈28 
Placebo≈25 
Baclofen≈9 Baclofen: 
18.4 
N/A N/A Baclofen:34 
Mean craving 
final baseline 
Baclofen≈6 
Placebo≈ 12 
Baclofen≈3 
Placebo≈7 
Baclofen≈0 Baclofen: 
12.4 
N/A N/A Baclofen 
<10 
Number of 
dropouts due 
to side effects 
0 0 0 2 0 0 0 
*Number needed to treat 
**Confidence Interval 
 
 
 
 
 
 
